Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 167.26 USD -1.24% Market Closed
Market Cap: 20.7B USD
Have any thoughts about
Natera Inc?
Write Note

Natera Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Natera Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Natera Inc
NASDAQ:NTRA
Pre-Tax Income
-$212.4m
CAGR 3-Years
19%
CAGR 5-Years
-12%
CAGR 10-Years
-34%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Natera Inc
Glance View

Market Cap
20.8B USD
Industry
Biotechnology

Natera Inc. is a leading genomics company that specializes in genetic testing and precision medicine, aiming to revolutionize healthcare through advanced DNA analysis. Founded in 2004 and headquartered in Austin, Texas, Natera focuses on reproductive health, oncology, and organ transplant management, providing invaluable insights that help doctors make informed decisions for their patients. Its flagship products include non-invasive prenatal testing (NIPT), which has gained significant traction for its ability to assess fetal health with remarkable accuracy, along with tests for hereditary cancer risk and monitoring treatment response in cancer patients. By harnessing the power of next-generation sequencing and machine learning, Natera is positioned to disrupt traditional medical practices and improve patient outcomes. Investors looking at Natera will find a company poised for growth amid increasing demand for genetic testing and personalized medicine. The company benefits from a robust pipeline and an expanding customer base, bolstered by strategic collaborations with healthcare providers and insurance companies. As awareness of genetic testing continues to rise, Natera's innovative solutions could capture substantial market share, particularly in oncology, where early detection can dramatically impact treatment efficacy and survival rates. With strong financial backing, a commitment to research and development, and a vision to elevate the standard of care through data-driven insights, Natera represents a compelling opportunity for those seeking to invest in the future of healthcare.

NTRA Intrinsic Value
56.65 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Natera Inc's Pre-Tax Income?
Pre-Tax Income
-212.4m USD

Based on the financial report for Sep 30, 2024, Natera Inc's Pre-Tax Income amounts to -212.4m USD.

What is Natera Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-34%

Over the last year, the Pre-Tax Income growth was 57%. The average annual Pre-Tax Income growth rates for Natera Inc have been 19% over the past three years , -12% over the past five years , and -34% over the past ten years .

Back to Top